3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, T-Cell, Peripheral
2
Hodgkin Disease
2
Recurrence
1
Interventions
10-propargyl-10-deazaaminopterin
12
Cyclophosphamide
8
Prednisone
7
belinostat
6
Vincristine
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Doxorubicin
6
Brentuximab Vedotin
5
romidepsin
4
mogamulizumab
4
darinaparsin
4
Vitamin B 12
4
Gemcitabine
4
Folic Acid
4
selinexor
3
denileukin diftitox
3
Nivolumab
3
Injections
3
Bendamustine Hydrochloride
3
tislelizumab
2
tipifarnib
2
tenalisib
2
duvelisib
2
Rituximab
2
Lenalidomide
2
HBI-8000
2
Fenretinide
2
E7777 fusion protein
2
AFM13
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Peripheral
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts
NCT04101331
2024-11-05
REDIRECT
Affimed GmbH
Phase 2
Completed
108 enrolled
24 charts